| Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT02122081) | Sumithira Vasu | 2015-07-27 |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02299518) | Alice Mims | 2015-05-18 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02316964) | Sumithira Vasu | 2015-04-21 |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (NCT01849276) | Northwestern University | 2015-03-11 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02049801) | Bruno C. Medeiros | 2014-12-01 |
| Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT02071901) | Case Comprehensive Cancer Center | 2014-08-14 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02029417) | Roswell Park Cancer Institute | 2014-07-01 |
| Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML (NCT02094794) | City of Hope Medical Center | 2014-05-12 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02030405) | Steven E. Coutre | 2014-03-01 |
| CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02019069) | Rondeep Brar | 2014-02-03 |
| AML Therapy With Irradiated Allogeneic Cells (NCT02105116) | Rutgers, The State University of New Jersey | 2014-02-01 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01904643) | Stanford University | 2014-02-01 |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (NCT01798901) | Alison Walker | 2013-09-17 |
| Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01876953) | City of Hope Medical Center | 2013-09-13 |
| Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy (NCT01869114) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-07-08 |
| Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia (NCT01869777) | Wake Forest University Health Sciences | 2013-07-01 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01707004) | University of Wisconsin, Madison | 2013-05-16 |
| Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01831232) | Fred Hutchinson Cancer Center | 2013-05-01 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01835288) | Stanford University | 2013-05-01 |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01820624) | Paolo Caimi, MD | 2013-04-30 |
| Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01822015) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-03-15 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (NCT01801046) | University of Southern California | 2013-03-06 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01768897) | Wake Forest University Health Sciences | 2013-01-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT01519596) | Wake Forest University Health Sciences | 2012-10-01 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01839240) | University of Chicago | 2012-06-06 |
| Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (NCT01548911) | Wake Forest University Health Sciences | 2012-05-01 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant (NCT01558778) | Roswell Park Cancer Institute | 2012-05-01 |
| Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT01567059) | Fred Hutchinson Cancer Center | 2012-05-01 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT01550185) | Roswell Park Cancer Institute | 2012-05-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (NCT01842139) | University of Chicago | 2011-12-05 |
| Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (NCT01521936) | Roswell Park Cancer Institute | 2011-12-01 |
| Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission (NCT01465386) | Fred Hutchinson Cancer Center | 2011-11-01 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (NCT01555268) | Roswell Park Cancer Institute | 2011-10-31 |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (NCT01564277) | Roswell Park Cancer Institute | 2011-09-29 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01342887) | Fred Hutchinson Cancer Center | 2011-04-01 |
| Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01349972) | National Cancer Institute (NCI) | 2011-04-01 |
| Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01246622) | Roswell Park Cancer Institute | 2011-02-07 |
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02085408) | ECOG-ACRIN Cancer Research Group | 2011-02-04 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy (NCT01235572) | Fred Hutchinson Cancer Center | 2010-12-01 |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01253447) | National Cancer Institute (NCI) | 2010-10-01 |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (NCT01233921) | Martin, Paul | 2010-09-01 |
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies (NCT01175785) | Nohla Therapeutics, Inc. | 2010-08-01 |
| Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm (NCT01101880) | University of Washington | 2010-08-01 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (NCT01174888) | Alison Walker | 2010-08-01 |
| Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT01127009) | Case Comprehensive Cancer Center | 2010-07-01 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload (NCT01159067) | City of Hope Medical Center | 2010-07-01 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (NCT01159301) | National Cancer Institute (NCI) | 2010-06-01 |
| Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant (NCT01083706) | Fred Hutchinson Cancer Center | 2010-04-01 |
| Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (NCT01031368) | Nohla Therapeutics, Inc. | 2009-12-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (NCT00860574) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (NCT02144675) | Rutgers, The State University of New Jersey | 2009-01-01 |
| Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS (NCT00839982) | Fred Hutchinson Cancer Center | 2008-11-01 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00795002) | National Cancer Institute (NCI) | 2008-11-01 |
| Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (NCT00666588) | National Cancer Institute (NCI) | 2008-04-01 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia (NCT00602771) | National Cancer Institute (NCI) | 2008-01-01 |
| Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer (NCT00540995) | City of Hope Medical Center | 2007-06-11 |
| Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00492401) | National Cancer Institute (NCI) | 2007-05-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases (NCT00357708) | National Cancer Institute (NCI) | 2006-06-01 |
| PXD101 in Treating Patients With Acute Myeloid Leukemia (NCT00357032) | National Cancer Institute (NCI) | 2006-05-01 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (NCT00343798) | Fred Hutchinson Cancer Center | 2006-04-01 |
| Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia (NCT00322101) | Fred Hutchinson Cancer Center | 2006-01-01 |
| Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00131989) | National Cancer Institute (NCI) | 2005-06-01 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00101296) | National Cancer Institute (NCI) | 2004-10-01 |
| Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies (NCT01056614) | Fred Hutchinson Cancer Center | 2004-09-01 |
| S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (NCT00093418) | National Cancer Institute (NCI) | 2004-09-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00079378) | National Cancer Institute (NCI) | 2004-02-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT00119366) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00062075) | National Cancer Institute (NCI) | 2003-05-01 |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant (NCT00052598) | Fred Hutchinson Cancer Center | 2002-09-01 |
| A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) (NCT00045396) | National Cancer Institute (NCI) | 2002-06-01 |
| Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission (NCT00045435) | Fred Hutchinson Cancer Center | 2002-04-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00027872) | National Cancer Institute (NCI) | 2001-10-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (NCT00006363) | National Cancer Institute (NCI) | 2000-11-01 |
| Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (NCT00093743) | Fred Hutchinson Cancer Center | 2000-01-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission (NCT00005940) | Fred Hutchinson Cancer Center | 1999-10-01 |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT00008177) | Fred Hutchinson Cancer Center | 1999-07-27 |
| Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia (NCT00003875) | Fred Hutchinson Cancer Center | 1998-10-13 |
| Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00003190) | National Cancer Institute (NCI) | 1998-01-01 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (NCT01869803) | Wake Forest University Health Sciences | |